Wenting Liao | Experimental Research | Sun Yat-sen University Cancer Center-Sun Yat-sen University Cancer Center

Name: Wenting Liao

Title: Associate Professor

Email: liaowt@sysucc.org.cn

Phone:

Profile

Dr. Wenting Liao is an associate professor in Sun Yat-sen University Cancer Center. She obtained her Ph.D. degree in Sun Yat-sen University Cancer Center in 2008. She finished her postdoctoral training in Department of Pathology, Southern Medical University of China in 2010. From 2015 to 2018, she worked as a visiting scientist in the DePinho Laboratory at MD Anderson Cancer Center, US.

Interests

Colorectal cancer (CRC) is a major cause of cancer mortality worldwide. Despite improvements in systemic treatments for patients with metastatic disease, the 5-year survival rate remains poor. Immune checkpoint blockade (ICB) therapy has provided durable clinical responses in multiple difficult-to-treat tumor types. However, ICB has shown no activity in almost 95% percent of metastatic CRC. Our research focuses on dissecting the molecular mechanisms of immune evasion and resistance to immune therapy in metastatic CRC and KRAS mutated cancers with the goal of illuminating effective therapeutic strategies.

Education

2015-2018 Visiting Scientist, MD Anderson Cancer Center.

2010 Postdoc in Pathology, Southern Medical University, China.

2008 Ph.D. in Oncology, Sun Yat-sen University Cancer Center, China.

2005 M.S. in Oncology, Sun Yat-sen University Cancer Center, China.

2002 B.S. in Clinical Medicine, HengYang Medical School, Hengyang, China.

Publications

1. Huang C^#,Ou R^#, Chen X^#, Zhang Y, Li J, Liang Y, Zhu X, Liu L, LiM, Lin D, Qiu J, Liu G, Zhang L, Wu Y, Tang H, Liu Y, Liang L, Ding Y*,LiaoW*. Tumor cell-derived SPON2 promotes M2-polarized tumor-associatedmacrophage infiltration and cancer progression by activating PYK2 in CRC.J Exp ClinCancer Res. 2021 Sep 28;40(1):304.

2. Wang S^#, Qiu J^#, Liu L^#, Su C, Qi L,Huang C, Chen X, Zhang Y, Ye Y, Ding Y, Liang L*,LiaoW*.CREB5 promotes invasiveness and metastasis in colorectal cancer bydirectly activating MET.J Exp Clin Cancer Res. 2020 Aug25;39(1):168.

3. Zhu X^#, Wang F^#, Wu X, Li Z, Wang Z, Ren X, ZhouY, Song F, Liang Y, Zeng Z, Liao W, Ding Y,LiaoW*, Liang L*. FBX8 promotes metastatic dormancy of colorectal cancer inliver.Cell Death Dis. 2020 Aug14;11(8):622.

4. Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA*, DePinho RA*. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell. 2019 Apr 15;35(4):559-572.

5. Ye Y^#, Jiao H^#, Wang S^#, Xiao Z, Zhang D, Qiu J, Zhang L, Zhao Y, LiT, Liang-L,Liao W*, Ding Y*. Hypermethylation of DMTN promotesthe metastasis of colorectal cancer cells by regulating the actin cytoskeletonthrough Rac1 signaling activation. J Exp Clin Cancer Res. 2018 Dec4;37(1):299.

6.Jian Y^#,Wang M^#, Zhang Y, Ou R, Zhu Z, Ou Y, Chen X, Liang X, Ding Y*, SongL*, Xu X*,Liao W^*. JadefamilyPHD finger 3 (JADE3) increases cancer stemcell-like properties and tumorigenicity in colon cancer. Cancer Lett.2018 Apr 13;428:1-11.

7. Lin C^#,LiaoW^#,Jian Y^#, Peng Y, Zhang X, Ye L,Cui Y, Wang B, Wu X, Xiong Z, Wu S, Li J, Wang X*, Song L*. CGI-99 promotesbreast cancer metastasis via autocrine interleukin-6 signaling. Oncogene. 2017 Jun 29;36(26):3695-3705.

8. JiaoH^#, Ye Y^#,Yang R, Sun H, Wang S, Wang Y, Xiao Z, He L, Cai J, Wei W, Chen Y, Gu C, Cai Y,Hu Y, Lai Q, Qiu J, Liang , Cao G, Liao WT^*, Ding Y^*.Down-regulation of SAFB sustains the NF-kappaB pathway by targeting TAK1 duringthe progression of colorectal cancer. ClinCancer Res. 2017 Sep 14;32(22):7108

Updated November 2021 by International Office, Sun Yat-sen University Cancer Center

Our Experts